Search
Search Results
-
Imaging beta-amyloid (Aβ) burden in the brains of middle-aged individuals with alcohol-use disorders: a [11C]PIB PET study
No in vivo human studies have examined the prevalence of Alzheimer’s disease (AD) neuropathology in individuals with alcohol-use disorder (AUD),...
-
Clausena Harmandiana root extract attenuated cognitive impairments via reducing amyloid accumulation and neuroinflammation in Aβ1-42-induced rats
BackgroundAlzheimer’s disease (AD) pathogenesis is associated with amyloid-β (Aβ)-induced neuroinflammation. In AD, the activation of microglia...
-
Integrating TSPO PET imaging and transcriptomics to unveil the role of neuroinflammation and amyloid-β deposition in Alzheimer’s disease
PurposeDespite the revealed role of immunological dysfunctions in the development and progression of Alzheimer’s disease (AD) through animal and...
-
Amyloid-Related Imaging Abnormalities and Other MRI Findings in a Cognitively Unimpaired Population With and Without Cerebral Amyloid
BackgroundScreening data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) and Longitudinal Evaluation of Amyloid Risk and...
-
Anti-amyloid Antibody Therapies for Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common cause of dementia, which is characterized by a progressive neurodegenerative disorder that is extremely...
-
Monitoring synaptic pathology in Alzheimer’s disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives
Alzheimer’s disease (AD) is currently constrained by limited clinical treatment options. The initial pathophysiological event, which can be traced...
-
Tau pathology as determinant of changes in atrophy and cerebral blood flow: a multi-modal longitudinal imaging study
PurposeTau pathology is associated with concurrent atrophy and decreased cerebral blood flow (CBF) in Alzheimer’s disease (AD), but less is known...
-
A Novel Near-Infrared Fluorescence Probe THK-565 Enables In Vivo Detection of Amyloid Deposits in Alzheimer’s Disease Mouse Model
PurposeNoninvasive imaging of protein aggregates in the brain is critical for the early diagnosis, disease monitoring, and evaluation of the...
-
Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer’s Disease Treated with Anti-Amyloid Beta Therapy
Amyloid-related imaging abnormalities (ARIA) are adverse events reported in Alzheimer’s disease trials of anti-amyloid beta (Aβ) therapies. This...
-
Cross-Sectional and Longitudinal Comparison of Tau Imaging with 18F-MK6240 and 18F-Flortaucipir in Populations Matched for Age, MMSE and Brain Beta-Amyloid Burden
ObjectivesLongitudinal tau quantification may provide a useful marker of drug efficacy in clinical trials. Different tau PET tracers may have...
-
Scanning ultrasound-mediated memory and functional improvements do not require amyloid-β reduction
A prevalent view in treating age-dependent disorders including Alzheimer’s disease (AD) is that the underlying amyloid plaque pathology must be...
-
Plasma Oligomer β-Amyloid and White Matter Microstructural Integrity in Cognitively Normal Older Adults According to Cerebral Amyloid Deposition
BackgroundMultimer detection system-oligomeric amyloid-β (MDS-OAβ) measure plasma OAβ level, which is associated with earlier Alzheimer’s disease...
-
Decreased imaging time of amyloid PET using [18F]florbetapir can maintain quantitative accuracy
Shortening the amount of time required to acquire amyloid positron emission tomography (PET) brain images while maintaining the accuracy of...
-
Clinical Management in Alzheimer’s Disease in the Era of Disease-Modifying Therapies
Purpose of reviewDiscuss emerging anti-amyloid disease-modifying therapies for Alzheimer’s disease (AD) and outline how these therapies will change...
-
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model
IntroductionALZ-801/valiltramiprosate is an oral, small-molecule inhibitor of beta-amyloid (Aβ) aggregation and oligomer formation in late-stage...
-
The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
BackgroundAlzheimer’s disease (AD) is a worldwide public health problem and is difficult to cure. Drugs aimed at slowing the progression of the...
-
Multimodality imaging of neurodegenerative disorders with a focus on multiparametric magnetic resonance and molecular imaging
Neurodegenerative diseases afflict a large number of persons worldwide, with the prevalence and incidence of dementia rapidly increasing. Despite...
-
Aducanumab: an uprising hope with vague horizons
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Amyloid-beta (Aβ) deposition, is one of the processes involved in the...
-
Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future
Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer’s disease (AD), and its accumulation has been considered as the...
-
Impact of demographics and comorbid conditions on plasma biomarkers concentrations and their diagnostic accuracy in a memory clinic cohort
Plasma biomarkers have emerged as promising tools for identifying amyloid beta (Aβ) pathology. Before implementation in routine clinical practice,...
